Cytosorbents (NASDAQ:CTSO) Share Price Passes Above Two Hundred Day Moving Average – Here’s Why

Cytosorbents Co. (NASDAQ:CTSO)’s share price passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.05 and traded as high as $1.16. Cytosorbents shares last traded at $1.13, with a volume of 109,611 shares traded.

Analyst Ratings Changes

CTSO has been the subject of several research analyst reports. StockNews.com initiated coverage on Cytosorbents in a research report on Tuesday. They set a “hold” rating for the company. D. Boral Capital restated a “buy” rating and set a $10.00 price target on shares of Cytosorbents in a research report on Tuesday, February 25th. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Stock Performance

The firm has a 50-day moving average price of $1.06 and a 200 day moving average price of $1.05. The firm has a market capitalization of $61.79 million, a PE ratio of -3.14 and a beta of 0.78. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06.

Institutional Trading of Cytosorbents

Several hedge funds have recently modified their holdings of CTSO. Millennium Management LLC acquired a new stake in shares of Cytosorbents in the fourth quarter valued at $30,000. Renaissance Technologies LLC raised its stake in shares of Cytosorbents by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock valued at $80,000 after acquiring an additional 8,400 shares in the last quarter. Northern Trust Corp raised its stake in shares of Cytosorbents by 22.3% in the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after acquiring an additional 16,701 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Cytosorbents in the fourth quarter valued at $99,000. Finally, Geode Capital Management LLC raised its stake in shares of Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after acquiring an additional 32,415 shares in the last quarter. 32.87% of the stock is currently owned by institutional investors and hedge funds.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.